These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
187 related articles for article (PubMed ID: 16291008)
1. Reducing residual risk for patients on statin therapy: the potential role of combination therapy. Davidson MH Am J Cardiol; 2005 Nov; 96(9A):3K-13K; discussion 34K-35K. PubMed ID: 16291008 [TBL] [Abstract][Full Text] [Related]
2. Reducing the residual risk of 3-hydroxy-3-methylglutaryl coenzyme a reductase inhibitor therapy with combination therapy. Polonsky TS; Davidson MH Am J Cardiol; 2008 Apr; 101(8A):27B-35B. PubMed ID: 18375238 [TBL] [Abstract][Full Text] [Related]
3. Apolipoprotein modifying effects of statins and fibrate in various age groups of coronary artery disease patients. Sharma R; Mahajan M; Singh B; Bal BS; Kant R J Indian Med Assoc; 2006 Sep; 104(9):492-4, 496, 498. PubMed ID: 17388006 [TBL] [Abstract][Full Text] [Related]
4. Efficacy of atorvastatin after LDL-cholesterol-based dose selection in high risk dyslipidaemic patients: results of the target dose study. Ducobu J; Claeys M; Commers K; Van Mieghem W; Nachtergaele H; Vandenbroucke M; Deforce J Curr Med Res Opin; 2007 Aug; 23(8):1821-7. PubMed ID: 17609019 [TBL] [Abstract][Full Text] [Related]
5. Clinical significance of recent lipid trials on reducing risk in patients with type 2 diabetes mellitus. Jones PH Am J Cardiol; 2007 Feb; 99(4A):133B-140B. PubMed ID: 17307065 [TBL] [Abstract][Full Text] [Related]
6. Safety and efficacy of Atorvastatin-induced very low-density lipoprotein cholesterol levels in Patients with coronary heart disease (a post hoc analysis of the treating to new targets [TNT] study). LaRosa JC; Grundy SM; Kastelein JJ; Kostis JB; Greten H; Am J Cardiol; 2007 Sep; 100(5):747-52. PubMed ID: 17719314 [TBL] [Abstract][Full Text] [Related]
7. Focused atorvastatin therapy in managed-care patients with coronary heart disease and CKD. Koren MJ; Davidson MH; Wilson DJ; Fayyad RS; Zuckerman A; Reed DP; Am J Kidney Dis; 2009 May; 53(5):741-50. PubMed ID: 19216014 [TBL] [Abstract][Full Text] [Related]
8. Rationale for targeting multiple lipid pathways for optimal cardiovascular risk reduction. Ballantyne CM Am J Cardiol; 2005 Nov; 96(9A):14K-19K; discussion 34K-35K. PubMed ID: 16291009 [TBL] [Abstract][Full Text] [Related]
9. [Coronary disease prevention: only the inhibition of inflammation is important. Why lower lipids, too?]. Sudhop T; von Bergmann K MMW Fortschr Med; 2003 May; 145(21):19. PubMed ID: 12845862 [No Abstract] [Full Text] [Related]
10. Efficacy and safety of combination of extended release niacin and atorvastatin in patients with low levels of high density lipoprotein cholesterol. Harikrishnan S; Rajeev E; Tharakan JA; Titus T; Ajit Kumar VK; Sivasankaran S; Krishnamoorthy KM; Nair K Indian Heart J; 2008; 60(3):215-22. PubMed ID: 19240310 [TBL] [Abstract][Full Text] [Related]
11. Reducing cardiovascular risk in diabetes: beyond glycemic and blood pressure control. Hobbs FD Int J Cardiol; 2006 Jun; 110(2):137-45. PubMed ID: 16289373 [TBL] [Abstract][Full Text] [Related]
12. The efficacy of statin monotherapy uptitration versus switching to ezetimibe/simvastatin: results of the EASEGO study. Roeters van Lennep HW; Liem AH; Dunselman PH; Dallinga-Thie GM; Zwinderman AH; Jukema JW Curr Med Res Opin; 2008 Mar; 24(3):685-94. PubMed ID: 18226326 [TBL] [Abstract][Full Text] [Related]
13. Effect of intensive versus moderate lipid lowering on endothelial function and vascular responsiveness to angiotensin II in stable coronary artery disease. van der Harst P; Wagenaar LJ; Buikema H; Voors AA; Plokker HW; Morshuis WJ; Six AJ; Boonstra PW; Nickenig G; Wassmann S; van Veldhuisen DJ; van Gilst WH Am J Cardiol; 2005 Nov; 96(10):1361-4. PubMed ID: 16275178 [TBL] [Abstract][Full Text] [Related]
14. [To lessen the cardiovascular risk of the diabetic patient. Atorvastatin of use for diabetic patients without coronary disease, too]. MMW Fortschr Med; 2005 Aug; 147(33-34):51. PubMed ID: 16138641 [No Abstract] [Full Text] [Related]
15. Modifying plasma low-density lipoprotein and high-density lipoprotein cholesterol: what combinations are available in the future? Kastelein JJ Am J Cardiol; 2005 Nov; 96(9A):20K-27K; discussion 34K-35K. PubMed ID: 16291010 [TBL] [Abstract][Full Text] [Related]
16. [Prevention in coronary heart disease. Can a CSE inhibitor arrest calcium deposits?]. MMW Fortschr Med; 2001 Apr; 143(14):44. PubMed ID: 11340911 [No Abstract] [Full Text] [Related]
17. Unexpected and abnormally low HDL cholesterol levels on combination hypolipidemic therapy. Unnikrishnan R; Das R; Jaydip R; Sudhakaran C; Mohan V J Assoc Physicians India; 2009 Feb; 57():180-1. PubMed ID: 19582991 [TBL] [Abstract][Full Text] [Related]
18. Drug insight: the role of statins in combination with ezetimibe to lower LDL cholesterol. Gotto AM; Farmer JA Nat Clin Pract Cardiovasc Med; 2006 Dec; 3(12):664-72. PubMed ID: 17122799 [TBL] [Abstract][Full Text] [Related]
19. Effect of lowering LDL cholesterol substantially below currently recommended levels in patients with coronary heart disease and diabetes: the Treating to New Targets (TNT) study. Shepherd J; Barter P; Carmena R; Deedwania P; Fruchart JC; Haffner S; Hsia J; Breazna A; LaRosa J; Grundy S; Waters D Diabetes Care; 2006 Jun; 29(6):1220-6. PubMed ID: 16731999 [TBL] [Abstract][Full Text] [Related]
20. Achieving LDL cholesterol, non-HDL cholesterol, and apolipoprotein B target levels in high-risk patients: Measuring Effective Reductions in Cholesterol Using Rosuvastatin therapY (MERCURY) II. Ballantyne CM; Bertolami M; Hernandez Garcia HR; Nul D; Stein EA; Theroux P; Weiss R; Cain VA; Raichlen JS Am Heart J; 2006 May; 151(5):975.e1-9. PubMed ID: 16644314 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]